Table 2.
Acute thrombus | Chronic thrombus | ||
---|---|---|---|
(n = 205) | (n = 58) | p Values | |
Age (years old) | 65 ± 15 | 66 ± 17 | 0.83 |
Sex (Male) | 121 (59.0%) | 36 (62.1%) | 0.68 |
BMI (kg/m2) | 25.2 ± 5.1 | 24.4 ± 4.1 | 0.38 |
Clinical risk: high | 12 (5.9%) | 3 (5.2%) | 0.37 |
Intermediate | 69 (33.7%) | 25 (43.1%) | |
Low | 124 (60.5%) | 30 (51.7%) | |
Etiology: cancer | 82 (40.0%) | 19 (32.8%) | 0.32 |
APS and autoimmune disease | 8 (3.9%) | 2 (3.4%) | 1 |
Protein C or S deficiency | 2 (1.0%) | 0 (0%) | NA |
Recent surgery | 21 (10.2%) | 0 (0%) | NA |
Simplified PESI | 1.1 ± 0.9 | 1.1 ± 0.8 | 0.81 |
Deep vein thrombosisa | 46/61 | 13/18 | 0.79 |
Treatment: thrombolysis | 12 (5.9%) | 2 (3.4%) | 0.74 |
Heparin or LMWH | 81 (39.5%) | 20 (34.5%) | 0.52 |
Anticoagulant: warfarin | 132 (64.4%) | 34 (58.6%) | 0.174 |
NOAC | 18 (8.8%) | 3 (5.2%) | |
Platelet (103/µL) | 225 ± 118 | 230 ± 101 | 0.81 |
Data are presented as the mean ± SD or n (%).
There were many missing data, and they are presented as positive number/total number.
APS: antiphospholipid syndrome; BMI: body mass index; LMWH: low molecular weight heparin; NOAC: novel oral anticoagulant; PESI: pulmonary embolism severity index.